Travoprost

Travoprost is a synthetic prostaglandin F2alpha analogue and selective FP-receptor agonist that lowers intraocular pressure by enhancing uveoscleral outflow, making it a first-line topical therapy for open-angle glaucoma and ocular hypertension. Ophthalmic formulations demand exceptionally tight impurity control given direct ocular exposure. Simson Pharma offers a Travoprost reference standard together with its characterised impurities for stability and assay work.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Travoprost Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Travoprost
5,6-trans Travoprost
15-Keto Travoprost liquid
(3aR,4R,5R,6aS)-5-hydroxy-4-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-one
Travoprost Acid
15-epi Travoprost
Bimatoprost Impurity 6
Travoprost Epoxide
9-Keto Travoprost
15S-Travoprost
Travoprost Epoxide Derivative 1
Travoprost Epoxide Derivative 2
9-Dpp Travoprost
(+)-Fluprostenol Ethyl Ester
Travoprost-Z1
Travoprost Isopropyl ester H
Travoprost Impurity 1